Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - $40 million in non-dilutive capital drawn from Neumora’s existing facility with K2 HealthVentures

Neumora Therapeutics, Inc. a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Neumora today announced that it has drawn an additional $40 million from its existing venture debt facility with K2 HealthVentures. The additional $40 million in non-dilutive capital from this facility drawn, combined with the cash already on the Company’s balance sheet, further strengthens its financial position.